What is Adverum Biotechnologies Book Value per Share?
Adverum Biotechnologies's book value per share for the quarter that ended in Mar. 2024 was €16.53.
During the past 12 months, Adverum Biotechnologies's average Book Value Per Share Growth Rate was -44.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -43.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -20.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Adverum Biotechnologies was 5.80% per year. The lowest was -43.00% per year. And the median was -17.00% per year.
During the past 12 years, the highest P/B Ratio of Adverum Biotechnologies was 8.97. The lowest was 0.18. And the median was 1.00.
Adverum Biotechnologies Book Value per Share Historical Data
The historical data trend for Adverum Biotechnologies's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Adverum Biotechnologies Book Value per Share Chart
Competitive Comparison of Adverum Biotechnologies's Book Value per Share
For the Biotechnology subindustry, Adverum Biotechnologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adverum Biotechnologies's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where Adverum Biotechnologies's PB Ratio falls into.
Adverum Biotechnologies Book Value per Share Calculation
Adverum Biotechnologies's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Adverum Biotechnologies (STU:AVU0) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Adverum Biotechnologies Book Value per Share Related Terms
Thank you for viewing the detailed overview of Adverum Biotechnologies's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Adverum Biotechnologies (STU:AVU0) Business Description
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:AVU0 has been successfully added to your 